Annamaria Biroccio

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8711925/publications.pdf

Version: 2024-02-01

102	5,415	76326	91884
papers	citations	40 h-index	69 g-index

105	105	105	7233
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antiâ€tumoural activity of the Gâ€quadruplex ligand pyridostatin against BRCA1/2â€deficient tumours. EMBO Molecular Medicine, 2022, 14, e14501.	6.9	13
2	TRF2 cooperates with CTCF for controlling the oncomiR-193b-3p in colorectal cancer. Cancer Letters, 2022, 533, 215607.	7.2	9
3	Identification of Effective Anticancer G-Quadruplex-Targeting Chemotypes through the Exploration of a High Diversity Library of Natural Compounds. Pharmaceutics, 2021, 13, 1611.	4.5	12
4	Synthesis and Characterization of Bis-Triazolyl-Pyridine Derivatives as Noncanonical DNA-Interacting Compounds. International Journal of Molecular Sciences, 2021, 22, 11959.	4.1	5
5	Harnessing Omics Approaches on Advanced Preclinical Models to Discovery Novel Therapeutic Targets for the Treatment of Metastatic Colorectal Cancer. Cancers, 2020, 12, 1830.	3.7	2
6	Exploring the Interaction between the SWI/SNF Chromatin Remodeling Complex and the Zinc Finger Factor CTCF. International Journal of Molecular Sciences, 2020, 21, 8950.	4.1	14
7	TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. Journal of Experimental and Clinical Cancer Research, 2020, 39, 111.	8.6	14
8	Trifunctionalized Naphthalene Diimides and Dimeric Analogues as G-Quadruplex-Targeting Anticancer Agents Selected by Affinity Chromatography. International Journal of Molecular Sciences, 2020, 21, 1964.	4.1	20
9	Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders. European Journal of Pharmaceutical Sciences, 2020, 149, 105337.	4.0	15
10	BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nature Communications, 2019, 10, 3143.	12.8	141
11	Insights into telomeric G-quadruplex DNA recognition by HMGB1 protein. Nucleic Acids Research, 2019, 47, 9950-9966.	14.5	38
12	BRCA2 Deletion Induces Alternative Lengthening of Telomeres in Telomerase Positive Colon Cancer Cells. Genes, 2019, 10, 697.	2.4	13
13	Emerging roles of telomeric chromatin alterations in cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 21.	8.6	30
14	TRF2 positively regulates SULF2 expression increasing VEGF-A release and activity in tumor microenvironment. Nucleic Acids Research, 2019, 47, 3365-3382.	14.5	34
15	Chlorambucil targets <scp>BRCA</scp> 1/2â€deficient tumours and counteracts <scp>PARP</scp> inhibitor resistance. EMBO Molecular Medicine, 2019, 11, e9982.	6.9	26
16	Dyads of Gâ€Quadruplex Ligands Triggering DNA Damage Response and Tumour Cell Growth Inhibition at Subnanomolar Concentration. Chemistry - A European Journal, 2019, 25, 11085-11097.	3.3	14
17	Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein <scp>TRF</scp> 2. EMBO Journal, 2019, 38, .	7.8	49
18	Tailoring a lead-like compound targeting multiple G-quadruplex structures. European Journal of Medicinal Chemistry, 2019, 163, 295-306.	5.5	24

#	Article	IF	Citations
19	Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. Cell Death and Disease, 2018, 9, 996.	6.3	75
20	Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. Journal of Experimental and Clinical Cancer Research, 2018, 37, 57.	8.6	140
21	Tandem application of ligand-based virtual screening and G4-OAS assay to identify novel G-quadruplex-targeting chemotypes. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1341-1352.	2.4	35
22	Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment. Journal of Medicinal Chemistry, 2017, 60, 3626-3635.	6.4	24
23	<scp>BRCA</scp> 1 and <scp>BRCA</scp> 2 tumor suppressors protect against endogenous acetaldehyde toxicity. EMBO Molecular Medicine, 2017, 9, 1398-1414.	6.9	57
24	EMICORON: A multi-targeting G4 ligand with a promising preclinical profile. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1362-1370.	2.4	17
25	SIRT6 interacts with TRF2 and promotes its degradation in response to DNA damage. Nucleic Acids Research, 2017, 45, 1820-1834.	14.5	43
26	Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?. Journal of Experimental and Clinical Cancer Research, 2017, 36, 189.	8.6	30
27	Patient-derived xenografts: a relevant preclinical model for drug development. Journal of Experimental and Clinical Cancer Research, 2016, 35, 189.	8.6	109
28	Perylene and coronene derivatives binding to G-rich promoter oncogene sequences efficiently reduce their expression in cancer cells. Biochimie, 2016, 125, 223-231.	2.6	21
29	The telomeric protein AKTIP interacts with A- and B-type lamins and is involved in regulation of cellular senescence. Open Biology, 2016, 6, 160103.	3.6	29
30	A bimodal fluorescent and photocytotoxic naphthalene diimide for theranostic applications. Organic and Biomolecular Chemistry, 2016, 14, 7238-7249.	2.8	25
31	Intragenic G-quadruplex structure formed in the human CD133 and its biological and translational relevance. Nucleic Acids Research, 2016, 44, 1579-1590.	14.5	40
32	Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds. Molecular Cell, 2016, 61, 449-460.	9.7	185
33	Anacardic acid and thyroid hormone enhance cardiomyocytes production from undifferentiated mouse ES cells along functionally distinct pathways. Endocrine, 2016, 53, 681-688.	2.3	7
34	Abstract 266: The G-quadruplex ligand EMICORON potentiates the antitumor efficacy of chemotherapy on colon cancer experimental models. , 2016, , .		0
35	Identification of novel interactors of human telomeric G-quadruplex DNA. Chemical Communications, 2015, 51, 2964-2967.	4.1	31
36	Looking for Efficient Gâ€Quadruplex Ligands: Evidence for Selective Stabilizing Properties and Telomere Damage by Drugâ€Like Molecules. ChemMedChem, 2015, 10, 640-649.	3.2	46

#	Article	IF	Citations
37	A basal level of DNA damage and telomere deprotection increases the sensitivity of cancer cells to G-quadruplex interactive compounds. Nucleic Acids Research, 2015, 43, 1759-1769.	14.5	15
38	Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer. Molecular Cancer Therapeutics, 2015, 14, 2541-2551.	4.1	27
39	AKTIP/Ft1, a New Shelterin-Interacting Factor Required for Telomere Maintenance. PLoS Genetics, 2015, 11, e1005167.	3.5	38
40	Bis-indole derivatives with antitumor activity turn out to be specific ligands of human telomeric G-quadruplex. Frontiers in Chemistry, 2014, 2, 54.	3.6	24
41	A novel pathway links telomeres to NK-cell activity. OncoImmunology, 2014, 3, e27358.	4.6	8
42	Identification of novel RHPS4-derivative ligands with improved toxicological profiles and telomere-targeting activities. Journal of Experimental and Clinical Cancer Research, 2014, 33, 81.	8.6	32
43	Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. Nucleic Acids Research, 2014, 42, 2945-2957.	14.5	45
44	Evidence for G-quadruplex in the promoter ofÂVEGFR-2 and its targeting to inhibit tumor angiogenesis. Nucleic Acids Research, 2014, 42, 14083-14083.	14.5	0
45	Shading the TRF2 Recruiting Function: A New Horizon in Drug Development. Journal of the American Chemical Society, 2014, 136, 16708-16711.	13.7	23
46	Design and synthesis of a new dimeric xanthone derivative: enhancement of G-quadruplex selectivity and telomere damage. Organic and Biomolecular Chemistry, 2014, 12, 9572-9582.	2.8	14
47	Exploring the Chemical Space of G-Quadruplex Binders: Discovery of a Novel Chemotype Targeting the Human Telomeric Sequence. Journal of Medicinal Chemistry, 2013, 56, 9646-9654.	6.4	48
48	On and off-target effects of telomere uncapping G-quadruplex selective ligands based on pentacyclic acridinium salts. Journal of Experimental and Clinical Cancer Research, 2013, 32, 68.	8.6	22
49	TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nature Cell Biology, 2013, 15, 818-828.	10.3	99
50	Î²-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced Î²-catenin signaling. Oncogene, 2013, 32, 5066-5077.	5.9	79
51	Methods of studying telomere damage induced by quadruplex-ligand complexes. Methods, 2012, 57, 93-99.	3.8	16
52	Aromatic Core Extension in the Series of Nâ€Cyclic Bayâ€Substituted Perylene Gâ€Quadruplex Ligands: Increased Telomere Damage, Antitumor Activity, and Strong Selectivity for Neoplastic over Healthy Cells. ChemMedChem, 2012, 7, 2144-2154.	3.2	33
53	Shooting for Selective Druglike G-Quadruplex Binders: Evidence for Telomeric DNA Damage and Tumor Cell Death. Journal of Medicinal Chemistry, 2012, 55, 9785-9792.	6.4	53
54	N-Cyclic Bay-Substituted Perylene G-Quadruplex Ligands Have Selective Antiproliferative Effects on Cancer Cells and Induce Telomere Damage. Journal of Medicinal Chemistry, 2011, 54, 1140-1156.	6.4	51

#	Article	IF	Citations
55	Aromatase Inhibitor Exemestane has Antiproliferative Effects on Human Mesothelioma Cells. Journal of Thoracic Oncology, 2011, 6, 583-591.	1.1	10
56	Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft. Journal of Translational Medicine, 2011, 9, 125.	4.4	11
57	DNA Damage Persistence as Determinant of Tumor Sensitivity to the Combination of Topo I Inhibitors and Telomere-Targeting Agents. Clinical Cancer Research, 2011, 17, 2227-2236.	7.0	33
58	Smad-Interacting Protein-1 and MicroRNA 200 Family Define a Nitric Oxideâ€“Dependent Molecular Circuitry Involved in Embryonic Stem Cell Mesendoderm Differentiation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 898-907.	2.4	26
59	Inhibition of PARP activity by PJâ€34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line. Journal of Cellular Physiology, 2010, 222, 401-410.	4.1	21
60	PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy. Oncogene, 2010, 29, 6280-6293.	5.9	103
61	Antiproliferative effect of Aurora kinase targeting in mesothelioma. Lung Cancer, 2010, 70, 271-279.	2.0	20
62	TRF2 and Apollo Cooperate with Topoisomerase 2Î± to Protect Human Telomeres from Replicative Damage. Cell, 2010, 142, 230-242.	28.9	155
63	Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway. Nucleic Acids Research, 2009, 37, 5353-5364.	14.5	152
64	Î²-Arrestin links endothelin A receptor to Î²-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2806-2811.	7.1	159
65	G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors. Clinical Cancer Research, 2008, 14, 7284-7291.	7.0	82
66	Î³-Glutamylcysteine Synthetase Mediates the c-Myc-Dependent Response to Antineoplastic Agents in Melanoma Cells. Molecular Pharmacology, 2007, 72, 1015-1023.	2.3	13
67	Therapeutic integration of câ€myc and bclâ€2 antisense molecules with docetaxel in a preclinical model of hormoneâ€refractory prostate cancer. Prostate, 2007, 67, 1475-1485.	2.3	21
68	Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. Journal of Clinical Investigation, 2007, 117, 3236-3247.	8.2	212
69	TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells. European Journal of Cancer, 2006, 42, 1881-1888.	2.8	62
70	c-Myc Phosphorylation Is Required for Cellular Response to Oxidative Stress. Molecular Cell, 2006, 21, 509-519.	9.7	175
71	Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. Cell Death and Differentiation, 2005, 12, 1429-1438.	11.2	124
72	Antisense clusterin oligodeoxynucleotides increase the response ofHER-2 gene amplified breast cancer cells to Trastuzumab. Journal of Cellular Physiology, 2005, 204, 463-469.	4.1	38

#	Article	IF	Citations
73	Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biology and Therapy, 2005, 4, 866-871.	3.4	15
74	Biological Activity of the G-Quadruplex Ligand RHPS4 (3,11-Difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) Is Associated with Telomere Capping Alteration. Molecular Pharmacology, 2004, 66, 1138-1146.	2.3	134
75	Telomerase as a new target for the treatment of hormone-refractory prostate cancer. Endocrine-Related Cancer, 2004, 11, 407-421.	3.1	34
76	In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors. International Journal of Cancer, 2004, 110, 767-774.	5.1	25
77	Glutathione Depletion Induced by c-Myc Downregulation Triggers Apoptosis on Treatment with Alkylating Agents. Neoplasia, 2004, 6, 195-206.	5.3	45
78	Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia, 2004, 6, 195-206.	5.3	13
79	?-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. International Journal of Cancer, 2003, 104, 243-250.	5.1	72
80	The future of antisense therapy: combination with anticancer treatments. Oncogene, 2003, 22, 6579-6588.	5.9	79
81	Che-1 Arrests Human Colon Carcinoma Cell Proliferation by Displacing HDAC1 from the p21 Promoter. Journal of Biological Chemistry, 2003, 278, 36496-36504.	3.4	46
82	Telomere Dysfunction Increases Cisplatin and Ecteinascidin-743 Sensitivity of Melanoma Cells. Molecular Pharmacology, 2003, 63, 632-638.	2.3	27
83	Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1. British Journal of Cancer, 2003, 89, 1091-1095.	6.4	5
84	Inhibition of c-Myc Oncoprotein Limits the Growth of Human Melanoma Cells by Inducing Cellular Crisis. Journal of Biological Chemistry, 2003, 278, 35693-35701.	3.4	34
85	Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy. Journal of Clinical Oncology, 2003, 21, 927-931.	1.6	274
86	Inhibition of Telomerase Increases Resistance of Melanoma Cells to Temozolomide, but Not to Temozolomide Combined with Poly (ADP-Ribose) Polymerase Inhibitor. Molecular Pharmacology, 2003, 63, 192-202.	2.3	42
87	Glutathione Influences c-Myc-induced Apoptosis in M14 Human Melanoma Cells. Journal of Biological Chemistry, 2002, 277, 43763-43770.	3.4	47
88	Endothelin-1 Protects Ovarian Carcinoma Cells against Paclitaxel-Induced Apoptosis: Requirement for Akt Activation. Molecular Pharmacology, 2002, 61, 524-532.	2.3	132
89	Bclâ€2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIFâ€1mediated transcriptional activity. FASEB Journal, 2002, 16, 1453-1455.	0.5	117
90	Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clinical Science, 2002, 103, 302S-305S.	4.3	24

#	Article	IF	Citations
91	Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. European Journal of Cancer, 2002, 38, 2455-2462.	2.8	32
92	ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. International Journal of Cancer, 2002, 98, 463-469.	5.1	87
93	Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones. Oncogene, 2002, 21, 3011-3019.	5.9	29
94	c-Myb and Bcl-x Overexpression Predicts Poor Prognosis in Colorectal Cancer. American Journal of Pathology, 2001, 158, 1289-1299.	3.8	122
95	C-Myc Down-Regulation Increases Susceptibility to Cisplatin through Reactive Oxygen Species-Mediated Apoptosis in M14 Human Melanoma Cells. Molecular Pharmacology, 2001, 60, 174-182.	2.3	82
96	Bcl-2 overexpression decreases BCNU sensitivity of a human glioblastoma line through enhancement of catalase activity. Journal of Cellular Biochemistry, 2001, 83, 473-483.	2.6	14
97	Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Therapy, 2001, 8, 459-468.	4.6	60
98	bcl-2 over-expression enhances NF-?B activity and induces mmp-9 transcription in human MCF7ADR breast-cancer cells. , 2000, 86, 188-196.		89
99	Bclâ€2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression andin vivoangiogenesis in a breast carcinoma line. FASEB Journal, 2000, 14, 652-660.	0.5	115
100	Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule. Gene Therapy, 1999, 6, 1064-1072.	4.5	31
101	bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant mcf7 cells. , 1999, 82, 125-130.		31
102	Bclâ€2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB Journal, 1997, 11, 947-953.	0.5	126